Watch the on-demand session.
Learn from Nicole Curnutt, Ph.D. Candidate at Harvard University, presenting: Casein kinase 1 alpha degrader DEG-77 targets TP53 WT gynecologic cancers with MDM4 dependence and altered SWI/SNF.
Presented at Drafts & Discoveries, scientific exchange co-hosted by EditCo and Promega in Cambridge, MA, this session highlights CK1α as an emerging therapeutic target in oncology and how next-generation degraders like DEG-77 uncover vulnerabilities in TP53 wild-type gynecologic cancers. Nicole discusses how SWI/SNF-deficient ovarian and endometrial cancer models rely on MDM4 to suppress p53 activity, and how CK1α degradation can restore p53 function to trigger apoptosis and cell cycle arrest.
Interested in using custom cell models to study cancer dependencies and drug response?